<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">34204243</PMID><DateRevised><Year>2021</Year><Month>07</Month><Day>14</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Print">2076-0817</ISSN><JournalIssue CitedMedium="Print"><Volume>10</Volume><Issue>6</Issue><PubDate><Year>2021</Year><Month>Jun</Month><Day>17</Day></PubDate></JournalIssue><Title>Pathogens (Basel, Switzerland)</Title><ISOAbbreviation>Pathogens</ISOAbbreviation></Journal><ArticleTitle>Investigation of Long COVID Prevalence and Its Relationship to Epstein-Barr Virus Reactivation.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">763</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/pathogens10060763</ELocationID><Abstract><AbstractText>Coronavirus disease 2019 (COVID-19) patients sometimes experience long-term symptoms following resolution of acute disease, including fatigue, brain fog, and rashes. Collectively these have become known as long COVID. Our aim was to first determine long COVID prevalence in 185 randomly surveyed COVID-19 patients and, subsequently, to determine if there was an association between occurrence of long COVID symptoms and reactivation of Epstein-Barr virus (EBV) in 68 COVID-19 patients recruited from those surveyed. We found the prevalence of long COVID symptoms to be 30.3% (56/185), which included 4 initially asymptomatic COVID-19 patients who later developed long COVID symptoms. Next, we found that 66.7% (20/30) of long COVID subjects versus 10% (2/20) of control subjects in our primary study group were positive for EBV reactivation based on positive titers for EBV early antigen-diffuse (EA-D) IgG or EBV viral capsid antigen (VCA) IgM. The difference was significant (<i>p</i> &lt; 0.001, Fisher's exact test). A similar ratio was observed in a secondary group of 18 subjects 21-90 days after testing positive for COVID-19, indicating reactivation may occur soon after or concurrently with COVID-19 infection. These findings suggest that many long COVID symptoms may not be a direct result of the SARS-CoV-2 virus but may be the result of COVID-19 inflammation-induced EBV reactivation.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Gold</LastName><ForeName>Jeffrey E</ForeName><Initials>JE</Initials><AffiliationInfo><Affiliation>World Organization, Watkinsville, GA 30677, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Okyay</LastName><ForeName>Ramazan A</ForeName><Initials>RA</Initials><AffiliationInfo><Affiliation>Department of Public Health, Kahramanmara&#x15f; S&#xfc;t&#xe7;&#xfc; &#x130;mam University, Kahramanmara&#x15f; 46040, Turkey.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Licht</LastName><ForeName>Warren E</ForeName><Initials>WE</Initials><AffiliationInfo><Affiliation>Warren Alpert Medical School of Brown University, Providence, RI 02903, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hurley</LastName><ForeName>David J</ForeName><Initials>DJ</Initials><AffiliationInfo><Affiliation>College of Veterinary Medicine, University of Georgia, Athens, GA 30602, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2021</Year><Month>06</Month><Day>17</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Pathogens</MedlineTA><NlmUniqueID>101596317</NlmUniqueID><ISSNLinking>2076-0817</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">EBV</Keyword><Keyword MajorTopicYN="N">Epstein&#x2013;Barr virus</Keyword><Keyword MajorTopicYN="N">Epstein&#x2013;Barr virus reactivation</Keyword><Keyword MajorTopicYN="N">PACS</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">chronic COVID syndrome</Keyword><Keyword MajorTopicYN="N">coronavirus</Keyword><Keyword MajorTopicYN="N">long COVID</Keyword><Keyword MajorTopicYN="N">post-acute COVID-19 syndrome</Keyword></KeywordList><CoiStatement>The authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>5</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2021</Year><Month>6</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2021</Year><Month>6</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>7</Month><Day>2</Day><Hour>1</Hour><Minute>20</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>7</Month><Day>3</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>6</Month><Day>17</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34204243</ArticleId><ArticleId IdType="pmc">PMC8233978</ArticleId><ArticleId IdType="doi">10.3390/pathogens10060763</ArticleId><ArticleId IdType="pii">pathogens10060763</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Logue J.K., Franko N.M., McCulloch D.J., McDonald D., Magedson A., Wolf C.R., Chu H.Y. Sequelae in Adults at 6 Months After COVID-19 Infection. JAMA Netw. Open. 2021;4:e210830. doi: 10.1001/jamanetworkopen.2021.0830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.0830</ArticleId><ArticleId IdType="pmc">PMC7896197</ArticleId><ArticleId IdType="pubmed">33606031</ArticleId></ArticleIdList></Reference><Reference><Citation>Greenhalgh T., Knight M., A&#x2019;Court C., Buxton M., Husain L. Management of post-acute covid-19 in primary care. BMJ. 2020;370:m3026. doi: 10.1136/bmj.m3026.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.m3026</ArticleId><ArticleId IdType="pubmed">32784198</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Jahdhami I., Al-Naamani K., Al-Mawali A. The Post-acute COVID-19 Syndrome (Long COVID) Oman Med. J. 2021;36:e220. doi: 10.5001/omj.2021.91.</Citation><ArticleIdList><ArticleId IdType="doi">10.5001/omj.2021.91</ArticleId><ArticleId IdType="pmc">PMC7838343</ArticleId><ArticleId IdType="pubmed">33537155</ArticleId></ArticleIdList></Reference><Reference><Citation>Garrigues E., Janvier P., Kherabi Y., Le Bot A., Hamon A., Gouze H., Doucet L., Berkani S., Oliosi E., Mallart E., et al. Post-discharge persistent symptoms and health-related quality of life after hospitalization for COVID-19. J. Infect. 2020;81:e4&#x2013;e6. doi: 10.1016/j.jinf.2020.08.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jinf.2020.08.029</ArticleId><ArticleId IdType="pmc">PMC7445491</ArticleId><ArticleId IdType="pubmed">32853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Huang L., Wang Y., Li X., Ren L., Gu X., Kang L., Guo L., Liu M., Zhou X., et al. 6-month consequences of COVID-19 in patients discharged from hospital: A cohort study. Lancet. 2021;397:220&#x2013;232. doi: 10.1016/S0140-6736(20)32656-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)32656-8</ArticleId><ArticleId IdType="pmc">PMC7833295</ArticleId><ArticleId IdType="pubmed">33428867</ArticleId></ArticleIdList></Reference><Reference><Citation>Callard F., Perego E. How and why patients made Long Covid. Soc. Sci. Med. 2021;268:113426. doi: 10.1016/j.socscimed.2020.113426.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.socscimed.2020.113426</ArticleId><ArticleId IdType="pmc">PMC7539940</ArticleId><ArticleId IdType="pubmed">33199035</ArticleId></ArticleIdList></Reference><Reference><Citation>Neves M., Marinho-Dias J., Ribeiro J., Sousa H. Epstein-Barr virus strains and variations: Geographic or disease-specific variants? J. Med. Virol. 2017;89:373&#x2013;387. doi: 10.1002/jmv.24633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.24633</ArticleId><ArticleId IdType="pubmed">27430663</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda T., Yajima M., Ikuta K. Epstein-Barr virus strain variation and cancer. Cancer Sci. 2019;110:1132&#x2013;1139. doi: 10.1111/cas.13954.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cas.13954</ArticleId><ArticleId IdType="pmc">PMC6447851</ArticleId><ArticleId IdType="pubmed">30697862</ArticleId></ArticleIdList></Reference><Reference><Citation>Misko I.S., Cross S.M., Khanna R., Elliott S.L., Schmidt C., Pye S.J., Silins S.L. Crossreactive recognition of viral, self, and bacterial peptide ligands by human class I-restricted cytotoxic T lymphocyte clonotypes: Implications for molecular mimicry in autoimmune disease. Proc. Natl. Acad. Sci. USA. 1999;96:2279&#x2013;2284. doi: 10.1073/pnas.96.5.2279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.96.5.2279</ArticleId><ArticleId IdType="pmc">PMC26774</ArticleId><ArticleId IdType="pubmed">10051632</ArticleId></ArticleIdList></Reference><Reference><Citation>Houen G., Trier N.H. Epstein-Barr Virus and Systemic Autoimmune Diseases. Front. Immunol. 2020;11:587380. doi: 10.3389/fimmu.2020.587380.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.587380</ArticleId><ArticleId IdType="pmc">PMC7817975</ArticleId><ArticleId IdType="pubmed">33488588</ArticleId></ArticleIdList></Reference><Reference><Citation>Straus S.E., Tosato G., Armstrong G., Lawley T., Preble O.T., Henle W., Davey R., Pearson G., Epstein J., Brus I., et al. Persisting illness and fatigue in adults with evidence of Epstein-Barr virus infection. Ann. Intern. Med. 1985;102:7&#x2013;16. doi: 10.7326/0003-4819-102-1-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/0003-4819-102-1-7</ArticleId><ArticleId IdType="pubmed">2578268</ArticleId></ArticleIdList></Reference><Reference><Citation>Stowe R.P., Pierson D.L., Feeback D.L., Barrett A.D. Stress-induced reactivation of Epstein-Barr virus in astronauts. Neuroimmunomodulation. 2000;8:51&#x2013;58. doi: 10.1159/000026453.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000026453</ArticleId><ArticleId IdType="pubmed">10965229</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaade L., Kleines M., Hausler M. Application of virus-specific immunoglobulin M (IgM), IgG, and IgA antibody detection with a polyantigenic enzyme-linked immunosorbent assay for diagnosis of Epstein-Barr virus infections in childhood. J. Clin. Microbiol. 2001;39:3902&#x2013;3905. doi: 10.1128/JCM.39.11.3902-3905.2001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JCM.39.11.3902-3905.2001</ArticleId><ArticleId IdType="pmc">PMC88462</ArticleId><ArticleId IdType="pubmed">11682505</ArticleId></ArticleIdList></Reference><Reference><Citation>Smatti M.K., Al-Sadeq D.W., Ali N.H., Pintus G., Abou-Saleh H., Nasrallah G.K. Epstein-Barr Virus Epidemiology, Serology, and Genetic Variability of LMP-1 Oncogene Among Healthy Population: An Update. Front. Oncol. 2018;8:211. doi: 10.3389/fonc.2018.00211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fonc.2018.00211</ArticleId><ArticleId IdType="pmc">PMC6008310</ArticleId><ArticleId IdType="pubmed">29951372</ArticleId></ArticleIdList></Reference><Reference><Citation>Baeck M., Herman A. COVID toes: Where do we stand with the current evidence? Int. J. Infect. Dis. 2021;102:53&#x2013;55. doi: 10.1016/j.ijid.2020.10.021.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.10.021</ArticleId><ArticleId IdType="pmc">PMC7566763</ArticleId><ArticleId IdType="pubmed">33075530</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasl S.V., Evans A.S., Niederman J.C. Psychosocial risk factors in the developmental of infectious mononucleosis. Psychosom. Med. 1979;41:445&#x2013;466. doi: 10.1097/00006842-197910000-00002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/00006842-197910000-00002</ArticleId><ArticleId IdType="pubmed">231279</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaser R., Rice J., Sheridan J., Fertel R., Stout J., Speicher C., Pinsky D., Kotur M., Post A., Beck M., et al. Stress-related immune suppression: Health implications. Brain Behav. Immun. 1987;1:7&#x2013;20. doi: 10.1016/0889-1591(87)90002-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0889-1591(87)90002-X</ArticleId><ArticleId IdType="pubmed">2837297</ArticleId></ArticleIdList></Reference><Reference><Citation>Glaser R., Kiecolt-Glaser J. Stress-associated immune modulation and its implications for reactivation of latent herpesviruses. Hum. Herpesvirus Infect. 1994;13:245.</Citation></Reference><Reference><Citation>Chen T., Song J., Liu H., Zheng H., Chen C. Positive Epstein-Barr virus detection in coronavirus disease 2019 (COVID-19) patients. Sci. Rep. 2021;11:10902. doi: 10.1038/s41598-021-90351-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-90351-y</ArticleId><ArticleId IdType="pmc">PMC8149409</ArticleId><ArticleId IdType="pubmed">34035353</ArticleId></ArticleIdList></Reference><Reference><Citation>Paolucci S., Cassaniti I., Novazzi F., Fiorina L., Piralla A., Comolli G., Bruno R., Maserati R., Gulminetti R., Novati S., et al. EBV DNA increase in COVID-19 patients with impaired lymphocyte subpopulation count. Int. J. Infect. Dis. 2020;104:315&#x2013;319. doi: 10.1016/j.ijid.2020.12.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.12.051</ArticleId><ArticleId IdType="pmc">PMC7833117</ArticleId><ArticleId IdType="pubmed">33359064</ArticleId></ArticleIdList></Reference><Reference><Citation>Simonnet A., Engelmann I., Moreau A.S., Garcia B., Six S., Kalioubie A.E., Robriquet L., Hober D., Jourdain M. High incidence of Epstein-Barr virus, cytomegalovirus, and human-herpes virus-6 reactivations in critically-ill patients with Covid-19. Infect. Dis. Now. 2021;51:296&#x2013;299. doi: 10.1016/j.idnow.2021.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.idnow.2021.01.005</ArticleId><ArticleId IdType="pmc">PMC7816954</ArticleId><ArticleId IdType="pubmed">33495765</ArticleId></ArticleIdList></Reference><Reference><Citation>Lehner G.F., Klein S.J., Zoller H., Peer A., Bellmann R., Joannidis M. Correlation of interleukin-6 with Epstein-Barr virus levels in COVID-19. Crit. Care. 2020;24:657. doi: 10.1186/s13054-020-03384-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03384-6</ArticleId><ArticleId IdType="pmc">PMC7682685</ArticleId><ArticleId IdType="pubmed">33228750</ArticleId></ArticleIdList></Reference><Reference><Citation>Singh V., Upadhyay P., Reddy J., Granger J. SARS-CoV-2 Respiratory Co-Infections: Incidence of Viral and Bacterial Co-Pathogens. Int. J. Infect. Dis. 2021;105:617&#x2013;620. doi: 10.1016/j.ijid.2021.02.087.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2021.02.087</ArticleId><ArticleId IdType="pmc">PMC7905386</ArticleId><ArticleId IdType="pubmed">33640570</ArticleId></ArticleIdList></Reference><Reference><Citation>Dowd J.B., Palermo T., Brite J., McDade T.W., Aiello A. Seroprevalence of Epstein-Barr virus infection in U.S. children ages 6&#x2013;19, 2003&#x2013;2010. PLoS ONE. 2013;8:e64921. doi: 10.1371/journal.pone.0064921.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0064921</ArticleId><ArticleId IdType="pmc">PMC3661547</ArticleId><ArticleId IdType="pubmed">23717674</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer G. Simplicity through complexity: Immunoblot with recombinant antigens as the new gold standard in Epstein-Barr virus serology. Clin. Lab. 2001;47:223&#x2013;230.</Citation><ArticleIdList><ArticleId IdType="pubmed">11405600</ArticleId></ArticleIdList></Reference><Reference><Citation>Lam W.K.J., Jiang P., Chan K.C.A., Cheng S.H., Zhang H., Peng W., Tse O.Y.O., Tong Y.K., Gai W., Zee B.C.Y., et al. Sequencing-based counting and size profiling of plasma Epstein-Barr virus DNA enhance population screening of nasopharyngeal carcinoma. Proc. Natl. Acad. Sci. USA. 2018;115:E5115&#x2013;E5124. doi: 10.1073/pnas.1804184115.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1804184115</ArticleId><ArticleId IdType="pmc">PMC5984543</ArticleId><ArticleId IdType="pubmed">29760067</ArticleId></ArticleIdList></Reference><Reference><Citation>Chan K.C.A., Woo J.K.S., King A., Zee B.C.Y., Lam W.K.J., Chan S.L., Chu S.W.I., Mak C., Tse I.O.L., Leung S.Y.M., et al. Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer. N. Engl. J. Med. 2017;377:513&#x2013;522. doi: 10.1056/NEJMoa1701717.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1701717</ArticleId><ArticleId IdType="pubmed">28792880</ArticleId></ArticleIdList></Reference><Reference><Citation>Odumade O.A., Hogquist K.A., Balfour H.H., Jr. Progress and problems in understanding and managing primary Epstein-Barr virus infections. Clin. Microbiol. Rev. 2011;24:193&#x2013;209. doi: 10.1128/CMR.00044-10.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.00044-10</ArticleId><ArticleId IdType="pmc">PMC3021204</ArticleId><ArticleId IdType="pubmed">21233512</ArticleId></ArticleIdList></Reference><Reference><Citation>Drago F., Herzum A., Ciccarese G., Parodi A. May syphilis protect against human papillomavirus infection? An example of heterologous immunity. G. Ital. Dermatol. Venereol. 2019;154:719&#x2013;721. doi: 10.23736/S0392-0488.18.05985-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.23736/S0392-0488.18.05985-0</ArticleId><ArticleId IdType="pubmed">29600695</ArticleId></ArticleIdList></Reference><Reference><Citation>Spencer S.A., Fenske N.A., Espinoza C.G., Hamill J.R., Cohen L.E., Espinoza L.R. Granuloma annulare-like eruption due to chronic Epstein-Barr virus infection. Arch. Dermatol. 1988;124:250&#x2013;255. doi: 10.1001/archderm.1988.01670020068020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/archderm.1988.01670020068020</ArticleId><ArticleId IdType="pubmed">2829748</ArticleId></ArticleIdList></Reference><Reference><Citation>Goodlad J. Epstein-Barr Virus Associated Lymphoproliferative Disorders in the Skin.  [(accessed on 15 June 2021)]; Available online:  https://bit.ly/goodladj1.</Citation></Reference><Reference><Citation>Fiorini G.F., Sinico R.A., Winearls C., Custode P., De Giuli-Morghen C., D&#x2019;Amico G. Persistent Epstein-Barr virus infection in patients with type II essential mixed cryoglobulinemia. Clin. Immunol. Immunopathol. 1988;47:262&#x2013;269. doi: 10.1016/S0090-1229(88)80004-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0090-1229(88)80004-7</ArticleId><ArticleId IdType="pubmed">2836115</ArticleId></ArticleIdList></Reference><Reference><Citation>Ichinose K., Origuchi T., Tashiro N., Kawashiri S.Y., Iwamoto N., Fujikawa K., Aramaki T., Arima K., Tamai M., Yamasaki S., et al. An elderly patient with chronic active Epstein-Barr virus infection with mixed cryoglobulinemia and review of the literature. Mod. Rheumatol. 2013;23:1022&#x2013;1028. doi: 10.3109/s10165-012-0731-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/s10165-012-0731-9</ArticleId><ArticleId IdType="pubmed">22895834</ArticleId></ArticleIdList></Reference><Reference><Citation>Rabinowitz H.K. Infectious mononucleosis presenting as Raynaud&#x2019;s phenomenon. J. Fam. Pract. 1989;29:311&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pubmed">2769197</ArticleId></ArticleIdList></Reference><Reference><Citation>Blereau R.P. Idiopathic Raynaud Disease.  [(accessed on 15 June 2021)];Consultant360. 2013 194 Available online:  https://www.consultant360.com/article/idiopathic-raynaud-disease.</Citation></Reference><Reference><Citation>Nirenberg M.S., Herrera M. Foot manifestations in a patient with COVID-19 and Epstein-Barr virus: A case study. Foot. 2020;46:101707. doi: 10.1016/j.foot.2020.101707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.foot.2020.101707</ArticleId><ArticleId IdType="pmc">PMC7313890</ArticleId><ArticleId IdType="pubmed">33039244</ArticleId></ArticleIdList></Reference><Reference><Citation>Arslan F., Karagz E., Bekz H.S., Ceylan B., Mert A. Epstein-Barr virus-associated haemophagocytic lymphohistiocytosis presenting with acute sensorineural hearing loss: A case report and review of the literature. Infez. Med. 2017;25:277&#x2013;280.</Citation><ArticleIdList><ArticleId IdType="pubmed">28956548</ArticleId></ArticleIdList></Reference><Reference><Citation>Williams L.L., Lowery H.W., Glaser R. Sudden hearing loss following infectious mononucleosis: Possible effect of altered immunoregulation. Pediatrics. 1985;75:1020&#x2013;1027.</Citation><ArticleIdList><ArticleId IdType="pubmed">2987786</ArticleId></ArticleIdList></Reference><Reference><Citation>Sun R., Liu H., Wang X. Mediastinal Emphysema, Giant Bulla, and Pneumothorax Developed during the Course of COVID-19 Pneumonia. Korean J. Radiol. 2020;21:541&#x2013;544. doi: 10.3348/kjr.2020.0180.</Citation><ArticleIdList><ArticleId IdType="doi">10.3348/kjr.2020.0180</ArticleId><ArticleId IdType="pmc">PMC7183834</ArticleId><ArticleId IdType="pubmed">32207255</ArticleId></ArticleIdList></Reference><Reference><Citation>Fidan V. New type of corona virus induced acute otitis media in adult. Am. J. Otolaryngol. 2020;41:102487. doi: 10.1016/j.amjoto.2020.102487.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjoto.2020.102487</ArticleId><ArticleId IdType="pmc">PMC7161479</ArticleId><ArticleId IdType="pubmed">32336572</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechien J.R., Chiesa-Estomba C.M., Place S., Van Laethem Y., Cabaraux P., Mat Q., Huet K., Plzak J., Horoi M., Hans S., et al. Clinical and epidemiological characteristics of 1420 European patients with mild-to-moderate coronavirus disease 2019. J. Intern. Med. 2020;288:335&#x2013;344. doi: 10.1111/joim.13089.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/joim.13089</ArticleId><ArticleId IdType="pmc">PMC7267446</ArticleId><ArticleId IdType="pubmed">32352202</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y., Gao F. Clinical characteristics of primary and reactivated Epstein-Barr virus infection in children. J. Med. Virol. 2020;92:3709&#x2013;3716. doi: 10.1002/jmv.26202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26202</ArticleId><ArticleId IdType="pubmed">32558948</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimenti C., Verardo R., Grande C., Francone M., Frustaci A. Infarct-like myocarditis with coronary vasculitis and aneurysm formation caused by Epstein-Barr virus infection. ESC Heart Fail. 2020;7:938&#x2013;941. doi: 10.1002/ehf2.12611.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ehf2.12611</ArticleId><ArticleId IdType="pmc">PMC7261578</ArticleId><ArticleId IdType="pubmed">32187886</ArticleId></ArticleIdList></Reference><Reference><Citation>Chimenti C., Russo A., Pieroni M., Calabrese F., Verardo R., Thiene G., Russo M.A., Maseri A., Frustaci A. Intramyocyte detection of Epstein-Barr virus genome by laser capture microdissection in patients with inflammatory cardiomyopathy. Circulation. 2004;110:3534&#x2013;3539. doi: 10.1161/01.CIR.0000148823.08092.0E.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.CIR.0000148823.08092.0E</ArticleId><ArticleId IdType="pubmed">15557377</ArticleId></ArticleIdList></Reference><Reference><Citation>Binkley P.F., Cooke G.E., Lesinski A., Taylor M., Chen M., Laskowski B., Waldman W.J., Ariza M.E., Williams M.V., Jr., Knight D.A., et al. Evidence for the role of Epstein Barr Virus infections in the pathogenesis of acute coronary events. PLoS ONE. 2013;8:e54008. doi: 10.1371/journal.pone.0054008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0054008</ArticleId><ArticleId IdType="pmc">PMC3547968</ArticleId><ArticleId IdType="pubmed">23349778</ArticleId></ArticleIdList></Reference><Reference><Citation>Jaumally B.A., Salem A., Robinett K. Epstein-Barr Virus-Related Multisystem Failure in an Immunocompetent Young Man. Crit. Care Med. 2018;46:323. doi: 10.1097/01.ccm.0000528689.41046.a8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.ccm.0000528689.41046.a8</ArticleId></ArticleIdList></Reference><Reference><Citation>Young L.S., Yap L.F., Murray P.G. Epstein-Barr virus: More than 50 years old and still providing surprises. Nat. Rev. Cancer. 2016;16:789&#x2013;802. doi: 10.1038/nrc.2016.92.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrc.2016.92</ArticleId><ArticleId IdType="pubmed">27687982</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoshino Y., Katano H., Zou P., Hohman P., Marques A., Tyring S.K., Follmann D., Cohen J.I. Long-term administration of valacyclovir reduces the number of Epstein-Barr virus (EBV)-infected B cells but not the number of EBV DNA copies per B cell in healthy volunteers. J. Virol. 2009;83:11857&#x2013;11861. doi: 10.1128/JVI.01005-09.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01005-09</ArticleId><ArticleId IdType="pmc">PMC2772668</ArticleId><ArticleId IdType="pubmed">19740997</ArticleId></ArticleIdList></Reference><Reference><Citation>Verma D., Thompson J., Swaminathan S. Spironolactone blocks Epstein-Barr virus production by inhibiting EBV SM protein function. Proc. Natl. Acad. Sci. USA. 2016;113:3609&#x2013;3614. doi: 10.1073/pnas.1523686113.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1523686113</ArticleId><ArticleId IdType="pmc">PMC4822607</ArticleId><ArticleId IdType="pubmed">26976570</ArticleId></ArticleIdList></Reference><Reference><Citation>Kotfis K., Lechowicz K., Drozdzal S., Niedzwiedzka-Rystwej P., Wojdacz T.K., Grywalska E., Biernawska J., Wisniewska M., Parczewski M. COVID-19-The Potential Beneficial Therapeutic Effects of Spironolactone during SARS-CoV-2 Infection. Pharmaceuticals. 2021;14:71. doi: 10.3390/ph14010071.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ph14010071</ArticleId><ArticleId IdType="pmc">PMC7830835</ArticleId><ArticleId IdType="pubmed">33477294</ArticleId></ArticleIdList></Reference><Reference><Citation>Mareev V.Y., Orlova Y.A., Plisyk A.G., Pavlikova E.P., Matskeplishvili S.T., Akopyan Z.A., Seredenina E.M., Potapenko A.V., Agapov M.A., Asratyan D.A., et al. Results of Open-Label non-Randomized Comparative Clinical Trial: &#x201c;BromhexIne and Spironolactone for Coronsmall a, CyrillicvirUs Infection requiring hospiTalization (BISCUIT) Kardiologiia. 2020;60:4&#x2013;15. doi: 10.18087/cardio.2020.11.n1440.</Citation><ArticleIdList><ArticleId IdType="doi">10.18087/cardio.2020.11.n1440</ArticleId><ArticleId IdType="pubmed">33487145</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu J., Zhang S., Wu Z., Shang Y., Dong X., Li G., Zhang L., Chen Y., Ye X., Du H., et al. Clinical outcomes of COVID-19 in Wuhan, China: A large cohort study. Ann. Intensive Care. 2020;10:99. doi: 10.1186/s13613-020-00706-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13613-020-00706-3</ArticleId><ArticleId IdType="pmc">PMC7393341</ArticleId><ArticleId IdType="pubmed">32737627</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>